Key result
Baseline HbA1c ≥ 7% linked to ~57% higher long-term major bleeding risk after NSTE-ACS PCI.
Why the study?
The association between baseline hemoglobin A1c levels and bleeding risk in NSTE-ACS patients undergoing PCI was unclear.
Cohort (n=6,283)
Yes
Answers are grounded in this paper and cite their sources.
Elevated baseline HbA1c signals higher post-PCI bleeding risk in NSTE-ACS; hypothesis-generating and should not yet change practice.
OBJECTIVE: To investigate the association between baseline hemoglobin A1c (HbA1c) levels and bleeding in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) who underwent percutaneous coronary intervention (PCI). METHODS: = 1543). The primary outcomes are major bleeding (BARC grades 3-5) and all-cause death during follow-up. CONCLUSIONS: Compared with the lower baseline HbA1c levels, the higher baseline HbA1c levels were associated with an increase in long-term bleeding risk in NSTE-ACS patients undergoing PCI, though higher baseline HbA1c levels were not associated with the higher risk in all-cause death.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2022) conducted a cohort in Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergoing PCI (n=6,283). Baseline HbA1c ≥ 7% vs. Baseline HbA1c < 7% was evaluated on Major bleeding (BARC grades 3-5) during long-term follow-up (adjusted HR 1.57, 95% CI 1.01-2.44, p=0.044). Compared with baseline HbA1c < 7%, baseline HbA1c levels ≥ 7% were associated with a higher long-term risk of major bleeding in patients with NSTE-ACS undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: